Style | Citing Format |
---|---|
MLA | Ghasemali S, et al.. "Rational Design of Anti-Angiogenic Peptides to Inhibit Vegf/Vegfr2 Interactions for Cancer Therapeutics." Anti-Cancer Agents in Medicinal Chemistry, vol. 22, no. 10, 2022, pp. 2026-2035. |
APA | Ghasemali S, Farajnia S, Barzegar A, Rahmati M, Negahdari B, Rahbarnia L, Yousefinodeh H (2022). Rational Design of Anti-Angiogenic Peptides to Inhibit Vegf/Vegfr2 Interactions for Cancer Therapeutics. Anti-Cancer Agents in Medicinal Chemistry, 22(10), 2026-2035. |
Chicago | Ghasemali S, Farajnia S, Barzegar A, Rahmati M, Negahdari B, Rahbarnia L, Yousefinodeh H. "Rational Design of Anti-Angiogenic Peptides to Inhibit Vegf/Vegfr2 Interactions for Cancer Therapeutics." Anti-Cancer Agents in Medicinal Chemistry 22, no. 10 (2022): 2026-2035. |
Harvard | Ghasemali S et al. (2022) 'Rational Design of Anti-Angiogenic Peptides to Inhibit Vegf/Vegfr2 Interactions for Cancer Therapeutics', Anti-Cancer Agents in Medicinal Chemistry, 22(10), pp. 2026-2035. |
Vancouver | Ghasemali S, Farajnia S, Barzegar A, Rahmati M, Negahdari B, Rahbarnia L, et al.. Rational Design of Anti-Angiogenic Peptides to Inhibit Vegf/Vegfr2 Interactions for Cancer Therapeutics. Anti-Cancer Agents in Medicinal Chemistry. 2022;22(10):2026-2035. |
BibTex | @article{ author = {Ghasemali S and Farajnia S and Barzegar A and Rahmati M and Negahdari B and Rahbarnia L and Yousefinodeh H}, title = {Rational Design of Anti-Angiogenic Peptides to Inhibit Vegf/Vegfr2 Interactions for Cancer Therapeutics}, journal = {Anti-Cancer Agents in Medicinal Chemistry}, volume = {22}, number = {10}, pages = {2026-2035}, year = {2022} } |
RIS | TY - JOUR AU - Ghasemali S AU - Farajnia S AU - Barzegar A AU - Rahmati M AU - Negahdari B AU - Rahbarnia L AU - Yousefinodeh H TI - Rational Design of Anti-Angiogenic Peptides to Inhibit Vegf/Vegfr2 Interactions for Cancer Therapeutics JO - Anti-Cancer Agents in Medicinal Chemistry VL - 22 IS - 10 SP - 2026 EP - 2035 PY - 2022 ER - |